

Bettina E Hansen

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1584448/bettina-e-hansen-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

223
papers

14,775
citations

60
h-index

116
g-index

231
ext. papers

17,300
ext. citations

6.3
avg, IF

6
L-index

#	Paper	IF	Citations
223	Outcomes of Adult Liver Retransplantation: A Canadian National Database Analysis.. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2022 , 2022, 9932631	2.8	
222	Dynamic risk profiling of hepatocellular carcinoma recurrence after curative intent liver resection.. <i>Hepatology</i> , 2022 ,	11.2	2
221	Reply to: Letter to the editor: Cautious use of multistate modeling in prognosis analysis of hepatocellular carcinoma.. <i>Hepatology</i> , 2022 ,	11.2	
220	Hepatitis B virus RNA decline without concomitant viral antigen decrease is associated with a low probability of sustained response and hepatitis B surface antigen loss. <i>Alimentary Pharmacology and Therapeutics</i> , 2021 , 53, 314-320	6.1	8
219	Evaluation of Sustained Virologic Response as a Relevant Surrogate Endpoint for Long-term Outcomes of Hepatitis C Virus Infection. <i>Clinical Infectious Diseases</i> , 2021 , 72, 780-786	11.6	2
218	Off-therapy response after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B: An international, multi-center, multi-ethnic cohort (RETRACT-B study). <i>Gastroenterology</i> , 2021 ,	13.3	9
217	Measurement of Gamma Glutamyl Transferase to Determine Risk of Liver Transplantation or Death in Patients With Primary Biliary Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 1688-1697.e14 ⁵	6.9	15
216	Spontaneous Clearance After Relapse Following Direct-Acting Antiviral Treatment for Chronic HCV Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 2398-2406.e1	6.9	0
215	Ultra-Long-term Follow-up of Interferon Alfa Treatment for HBeAg-Positive Chronic Hepatitis B Virus Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 1933-1940.e1	6.9	2
214	Blood Cell Salvage and Autotransfusion Does Not Worsen Oncologic Outcomes Following Liver Transplantation with Incidental Hepatocellular Carcinoma: A Propensity Score-Matched Analysis. <i>Annals of Surgical Oncology</i> , 2021 , 28, 6816-6825	3.1	1
213	Novel biomarker for hepatocellular carcinoma: high tumoral PLK-4 expression is associated with better prognosis in patients without microvascular invasion. <i>Hpb</i> , 2021 , 23, 359-366	3.8	
212	Effectiveness and Renal Safety of Tenofovir Alafenamide Fumarate among Chronic Hepatitis B Patients: Real-World Study. <i>Journal of Viral Hepatitis</i> , 2021 , 28, 942-950	3.4	2
211	A Comparison of Prognostic Scores (Mayo, UK-PBC, and GLOBE) in Primary Biliary Cholangitis. <i>American Journal of Gastroenterology</i> , 2021 , 116, 1514-1522	0.7	1
210	Predictive performance of newer Asian hepatocellular carcinoma risk scores in treated Caucasians with chronic hepatitis B. <i>JHEP Reports</i> , 2021 , 3, 100290	10.3	0
209	Association Between Seroclearance of Hepatitis B Surface Antigen and Long-term Clinical Outcomes of Patients With Chronic Hepatitis B Virus Infection: Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 463-472	6.9	15
208	Obeticholic acid is associated with improvements in AST-to-platelet ratio index and GLOBE score in patients with primary biliary cholangitis. <i>JHEP Reports</i> , 2021 , 3, 100191	10.3	6
207	Antibodies to gp210 and understanding risk in patients with primary biliary cholangitis. <i>Liver International</i> , 2021 , 41, 535-544	7.9	3

206	Maintained virological suppression and renal function with reduced dose tenofovir disoproxil fumarate in renally impaired chronic hepatitis B patients. <i>Journal of Viral Hepatitis</i> , 2021 , 28, 51-60	3.4	1
205	Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity. <i>Journal of Hepatology</i> , 2021 , 74, 1053-1063	13.4	23
204	Hepatitis B Virus RNA as Early Predictor for Response to Pegylated Interferon Alpha in HBeAg-Negative Chronic Hepatitis B. <i>Clinical Infectious Diseases</i> , 2021 , 72, 202-211	11.6	17
203	Serum hepatitis B virus RNA level is associated with biochemical relapse in patients with chronic hepatitis B infection who discontinue nucleos(t)ide analogue treatment. <i>Alimentary Pharmacology and Therapeutics</i> , 2021 , 54, 709-714	6.1	2
202	Association of bezafibrate with transplant-free survival in patients with primary biliary cholangitis. <i>Journal of Hepatology</i> , 2021 , 75, 565-571	13.4	8
201	Mean HBsAg decline at week 24 of PEG-IFN-based treatment predicts subsequent rate of HBsAg clearance - suggesting a valuable endpoint for early development HBV trials. <i>Journal of Viral Hepatitis</i> , 2021 , 28, 1563-1569	3.4	0
200	Combination of FIB-4 with ultrasound surface nodularity or elastography as predictors of histologic advanced liver fibrosis in chronic liver disease. <i>Scientific Reports</i> , 2021 , 11, 19275	4.9	0
199	Effects of on-treatment ALT flares on serum HBsAg and HBV RNA in patients with chronic HBV infection. <i>Journal of Viral Hepatitis</i> , 2021 , 28, 1729-1737	3.4	0
198	Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B. <i>JHEP Reports</i> , 2021 , 3, 100350	10.3	7
197	Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2020 , 73, 1037-1045	13.4	34
196	Alcohol, tobacco and coffee consumption and liver disease severity among individuals with Chronic Hepatitis B infection in North America. <i>Annals of Hepatology</i> , 2020 , 19, 437-445	3.1	2
195	Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase. <i>American Journal of Gastroenterology</i> , 2020 , 115, 1066-1074	0.7	31
194	Real-World Effectiveness of Obeticholic Acid in Patients with Primary Biliary Cholangitis. <i>Hepatology Communications</i> , 2020 , 4, 1332-1345	6	12
193	Serum hepatitis B virus RNA predicts response to peginterferon treatment in HBeAg-positive chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2020 , 27, 610-619	3.4	12
192	Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2020 , 72, 1088-1096	13.4	50
191	Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis. <i>Journal of Hepatology</i> , 2020 , 73, 559-565	13.4	21
190	hbsag levels can be used to rule out cirrhosis in hbeag positive chronic hepatitis b: results from the sonic-b study. <i>Journal of Infectious Diseases</i> , 2020 ,	7	5
189	Very low probability of significant liver inflammation in chronic hepatitis B patients with low ALT levels in the absence of liver fibrosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 52, 1399-1406	6.1	5

188	Simplified care-pathway selection for nonspecialist practice: the GLOBAL Primary Biliary Cholangitis Study Group Age, Bilirubin, Alkaline phosphatase risk assessment tool. <i>European Journal of Gastroenterology and Hepatology</i> , 2020 , 33,	2.2	1
187	Risk of gallbladder cancer in patients with primary sclerosing cholangitis and radiographically detected gallbladder polyps. <i>Liver International</i> , 2020 , 40, 382-392	7.9	7
186	The Impact of Direct-acting Antivirals on Overall Mortality and Tumoral Recurrence in Patients With Hepatocellular Carcinoma Listed for Liver Transplantation: An International Multicenter Study. <i>Transplantation</i> , 2020 , 104, 2087-2096	1.8	7
185	Factors Associated With Progression and Outcomes of Early Stage Primary Biliary Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 684-692.e6	6.9	10
184	No Superiority of Tacrolimus Suppositories vs Beclomethasone Suppositories in a Randomized Trial of Patients With Refractory Ulcerative Proctitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 1777-1784.e2	6.9	52
183	Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis. <i>Gut</i> , 2020 , 69, 1502-1509	19.2	13
182	Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial (Toronto STOP study). <i>Gut</i> , 2019 , 68, 2206-2213	19.2	59
181	Hepatitis C Core-Antigen Testing from Dried Blood Spots. <i>Viruses</i> , 2019 , 11,	6.2	10
180	Low hepatitis B surface antigen and HBV DNA levels predict response to the addition of pegylated interferon to entecavir in hepatitis B e antigen positive chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 49, 448-456	6.1	15
179	Hepatitis B core-related antigen monitoring during peginterferon alfa treatment for HBeAg-negative chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2019 , 26, 1156-1163	3.4	10
178	Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 2076-2084.e2	6.9	27
177	Prevalence and predictors of complementary and alternative medicine modalities in patients with chronic hepatitis B. <i>Liver International</i> , 2019 , 39, 1418-1427	7.9	4
176	Optimisation of the use of APRI and FIB-4 to rule out cirrhosis in patients with chronic hepatitis B: results from the SONIC-B study. <i>The Lancet Gastroenterology and Hepatology</i> , 2019 , 4, 538-544	18.8	29
175	Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis. <i>Journal of Hepatology</i> , 2019 , 71, 357-365	13.4	80
174	Association Between Severe Serum Alanine Aminotransferase Flares and Hepatitis B e Antigen Seroconversion and HBV DNA Decrease in Untreated Patients With Chronic HBV Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 2541-2551.e2	6.9	15
173	Genome-wide Association Study Identifies Genetic Variants Associated With Early and Sustained Response to (Pegylated) Interferon in Chronic Hepatitis B Patients: The GIANT-B Study. <i>Clinical Infectious Diseases</i> , 2019 , 69, 1969-1979	11.6	7
172	Caucasian Ethnicity, but Not Treatment Cessation is Associated with HBsAg Loss Following Nucleos(t)ide Analogue-Induced HBeAg Seroconversion. <i>Viruses</i> , 2019 , 11,	6.2	6
171	Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 50, 1127-1136	6.1	29

170	Long-term follow-up of patients treated with entecavir and peginterferon add-on therapy for HBeAg-positive chronic hepatitis B infection: ARES long-term follow-up. <i>Journal of Viral Hepatitis</i> , 2019 , 26, 109-117	3.4	13
169	Trends in liver transplantation for primary biliary cholangitis in Europe over the past three decades. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 49, 285-295	6.1	26
168	Factors Associated With Recurrence of Primary Biliary Cholangitis After Liver Transplantation and Effects on Graft and Patient Survival. <i>Gastroenterology</i> , 2019 , 156, 96-107.e1	13.3	52
167	Serum Level of Antibodies Against Hepatitis B Core Protein Is Associated With Clinical Relapse After Discontinuation of Nucleos(t)ide Analogue Therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 182-191.e1	6.9	35
166	Host and viral factors associated with serum hepatitis B virus RNA levels among patients in need for treatment. <i>Hepatology</i> , 2018 , 68, 839-847	11.2	46
165	Expanding the donor pool: Donation after circulatory death and living liver donation do not compromise the results of liver transplantation. <i>Liver Transplantation</i> , 2018 , 24, 779-789	4.5	42
164	Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population. <i>Journal of Hepatology</i> , 2018 , 68, 1129-1136	13.4	64
163	Risk stratification and prognostic modelling in primary biliary cholangitis. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , 2018 , 34-35, 95-106	2.5	5
162	Clinical application of the GLOBE and United Kingdom-primary biliary cholangitis risk scores in a trial cohort of patients with primary biliary cholangitis. <i>Hepatology Communications</i> , 2018 , 2, 683-692	6	11
161	Erythrocyte Inosine triphosphatase activity: A potential biomarker for adverse events during combination antiretroviral therapy for HIV. <i>PLoS ONE</i> , 2018 , 13, e0191069	3.7	4
160	Major Hepatic Complications in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis: Risk Factors and Time Trends in Incidence and Outcome. <i>American Journal of Gastroenterology</i> , 2018 , 113, 254-264	0.7	44
159	Milder disease stage in patients with primary biliary cholangitis over a 44-year period: A changing natural history. <i>Hepatology</i> , 2018 , 67, 1920-1930	11.2	35
158	Current policy for allocation of donor livers in the Netherlands advantages primary sclerosing cholangitis patients on the liver transplantation waiting list-a retrospective study. <i>Transplant International</i> , 2018 , 31, 590-599	3	5
157	Living Donor Liver Transplantation Using Selected Grafts With 2 Bile Ducts Compared With 1 Bile Duct Does Not Impact Patient Outcome. <i>Liver Transplantation</i> , 2018 , 24, 1512-1522	4.5	16
156	Off-Treatment Hepatitis B Virus (HBV) DNA Levels and the Prediction of Relapse After Discontinuation of Nucleos(t)ide Analogue Therapy in Patients With Chronic Hepatitis B: A Prospective Stop Study. <i>Journal of Infectious Diseases</i> , 2017 , 215, 581-589	7	43
155	The impact of infections on delisting patients from the liver transplantation waiting list. <i>Transplant International</i> , 2017 , 30, 807-816	3	7
154	The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B. <i>Hepatology</i> , 2017 , 66, 1444-1453	11.2	180
153	Coffee and herbal tea consumption is associated with lower liver stiffness in the general population: The Rotterdam study. <i>Journal of Hepatology</i> , 2017 , 67, 339-348	13.4	47

152	Durability of Response After Hepatitis B Surface Antigen Seroclearance During Nucleos(t)ide Analogue Treatment in a Multiethnic Cohort of Chronic Hepatitis B Patients: Results After Treatment Cessation. <i>Clinical Infectious Diseases</i> , 2017 , 65, 680-683	11.6	23
151	Pegylated Interferon Alfa-2b Add-on Treatment in Hepatitis B Virus Envelope Antigen-Positive Chronic Hepatitis B Patients Treated with Nucleos(t)ide Analogue: A Randomized, Controlled Trial (PEGON). <i>Journal of Infectious Diseases</i> , 2017 , 215, 1085-1093	7	33
150	Toronto HCC risk index: A validated scoring system to predict 10-year risk of HCC in patients with cirrhosis. <i>Journal of Hepatology</i> , 2017 ,	13.4	78
149	Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication. <i>Journal of Hepatology</i> , 2017 , 66, 485-493	13.4	160
148	Factors associated with ethnical disparity in overall survival for patients with hepatocellular carcinoma. <i>Oncotarget</i> , 2017 , 8, 15193-15204	3.3	16
147	A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. <i>New England Journal of Medicine</i> , 2016 , 375, 631-43	59.2	574
146	Testing for Anti-PBP Antibody Is Not Useful in Diagnosing Autoimmune Pancreatitis. <i>American Journal of Gastroenterology</i> , 2016 , 111, 1650-1654	0.7	7
145	Early biliary decompression versus conservative treatment in acute biliary pancreatitis (APEC trial): study protocol for a randomized controlled trial. <i>Trials</i> , 2016 , 17, 5	2.8	26
144	Improvement of platelets after SVR among patients with chronic HCV infection and advanced hepatic fibrosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016 , 31, 1168-76	4	33
143	Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study. <i>Gut</i> , 2016 , 65, 321-9	19.2	107
142	Immunological Analysis During Interferon-Free Therapy for Chronic Hepatitis C Virus Infection Reveals Modulation of the Natural Killer Cell Compartment. <i>Journal of Infectious Diseases</i> , 2016 , 213, 216-23	7	117
141	Percutaneous Transluminal Angioplasty and Drug-Eluting Stents for Infrapopliteal Lesions in Critical Limb Ischemia (PADI) Trial. <i>Circulation: Cardiovascular Interventions</i> , 2016 , 9, e002376	6	48
140	Repeated Measurements of Hepatitis B Surface Antigen Identify Carriers of Inactive HBV During Long-term Follow-up. <i>Clinical Gastroenterology and Hepatology</i> , 2016 , 14, 1481-1489.e5	6.9	36
139	PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. <i>Journal of Hepatology</i> , 2016 , 64, 800-6	13.4	227
138	Epidemiological trends among the population with chronic HCV infection in the Netherlands. <i>Antiviral Therapy</i> , 2016 , 21, 207-15	1.6	
137	Increased Hepatitis E Virus Seroprevalence Correlates with Lower CD4+ Cell Counts in HIV-Infected Persons in Argentina. <i>PLoS ONE</i> , 2016 , 11, e0160082	3.7	21
136	Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2016 , 14, 1821-1830.e6	6.9	46
135	Flares during long-term entecavir therapy in chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016 , 31, 1882-1887	4	7

134	Real-world medical costs of antiviral therapy among patients with chronic HCV infection and advanced hepatic fibrosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016 , 31, 1851-1859	4	4
133	Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: The Rotterdam study. <i>Hepatology</i> , 2016 , 63, 138-47	11.2	175
132	Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians. <i>Gut</i> , 2015 , 64, 1289-95	19.2	146
131	Risk of infections during interferon-based treatment in patients with chronic hepatitis C virus infection and advanced hepatic fibrosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015 , 30, 1057-64	4	4
130	Adding pegylated interferon to entecavir for hepatitis B e antigen-positive chronic hepatitis B: A multicenter randomized trial (ARES study). <i>Hepatology</i> , 2015 , 61, 1512-22	11.2	124
129	Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy. <i>Gastroenterology</i> , 2015 , 149, 1804-1812.e4	13.3	235
128	Liver Contrast-Enhanced Ultrasound Improves Detection of Liver Metastases in Patients with Pancreatic or Periampullary Cancer. <i>Ultrasound in Medicine and Biology</i> , 2015 , 41, 3063-9	3.5	9
127	Use of visible light spectroscopy to diagnose chronic gastrointestinal ischemia and predict response to treatment. <i>Clinical Gastroenterology and Hepatology</i> , 2015 , 13, 122-30.e1	6.9	15
126	Reliable prediction of clinical outcome in patients with chronic HCV infection and compensated advanced hepatic fibrosis: a validated model using objective and readily available clinical parameters. <i>Gut</i> , 2015 , 64, 322-31	19.2	28
125	The Long-Term Impact of Autoimmune Pancreatitis on Pancreatic Function, Quality of Life, and Life Expectancy. <i>Pancreas</i> , 2015 , 44, 1065-71	2.6	26
124	ITPA Polymorphisms Are Associated with Hematological Side Effects during Antiviral Therapy for Chronic HCV Infection. <i>PLoS ONE</i> , 2015 , 10, e0139317	3.7	10
123	Reply: To PMID 25160979. <i>Gastroenterology</i> , 2015 , 148, 860-1	13.3	
122	Surrogate Endpoints for Optimal Therapeutic Response to UDCA in Primary Biliary Cholangitis. <i>Digestive Diseases</i> , 2015 , 33 Suppl 2, 118-24	3.2	2
121	High-dose (peg)interferon therapy in treatment-naïve, interleukin-28B rs12979860 CT/TT genotype 1 chronic hepatitis C. <i>Digestive and Liver Disease</i> , 2015 , 47, 87-8	3.3	1
120	Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy. <i>Journal of Hepatology</i> , 2015 , 62, 956-67	13.4	285
119	Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI). <i>Gut</i> , 2014 , 63, 292-9	19.2	162
118	Immunoglobulin G4-related prostatitis: a case-control study focusing on clinical and pathologic characteristics. <i>Urology</i> , 2014 , 83, 521-6	1.6	31
117	Effect of thrombocytopenia on treatment tolerability and outcome in patients with chronic HCV infection and advanced hepatic fibrosis. <i>Journal of Hepatology</i> , 2014 , 61, 482-91	13.4	18

116	Is there sufficient evidence to recommend antiviral therapy in hepatitis C?. <i>Journal of Hepatology</i> , 2014 , 60, 191-6	13.4	30
115	Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. <i>Gastroenterology</i> , 2014 , 147, 1338-49.e5; quiz e15	13.3	265
114	Serum liver enzymes are associated with all-cause mortality in an elderly population. <i>Liver International</i> , 2014 , 34, 296-304	7.9	59
113	Comparable efficacy of low- versus high-dose induction corticosteroid treatment in autoimmune pancreatitis. <i>Pancreas</i> , 2014 , 43, 261-7	2.6	25
112	Drug therapies for ulcerative proctitis: systematic review and meta-analysis. <i>Inflammatory Bowel Diseases</i> , 2014 , 20, 2157-78	4.5	13
111	A comparative study of diagnostic scoring systems for autoimmune pancreatitis. <i>Pancreas</i> , 2014 , 43, 559-64	2.6	12
110	Life expectancy in patients with chronic HCV infection and cirrhosis compared with a general population. <i>JAMA - Journal of the American Medical Association</i> , 2014 , 312, 1927-8	27.4	68
109	Presence of anti-interferon antibodies is not associated with non-response to pegylated interferon treatment in chronic hepatitis B. <i>Antiviral Therapy</i> , 2014 , 19, 423-7	1.6	1
108	Long-term response rates of successful hepatitis B vaccination in HIV-infected patients. <i>Vaccine</i> , 2013 , 31, 1040-4	4.1	37
107	Serum levels of interferon-gamma-inducible protein 10 and response to peginterferon therapy in HBeAg-positive chronic hepatitis B. <i>Journal of Hepatology</i> , 2013 , 58, 898-903	13.4	40
106	MicroRNA profiles in graft preservation solution are predictive of ischemic-type biliary lesions after liver transplantation. <i>Journal of Hepatology</i> , 2013 , 59, 1231-8	13.4	44
105	Hepatitis B e antigen levels and response to peginterferon: influence of precore and basal core promoter mutants. <i>Antiviral Research</i> , 2013 , 97, 312-7	10.8	15
104	External validation of the fatty liver index for identifying nonalcoholic fatty liver disease in a population-based study. <i>Clinical Gastroenterology and Hepatology</i> , 2013 , 11, 1201-4	6.9	128
103	Close monitoring of hepatitis B surface antigen levels helps classify flares during peginterferon therapy and predicts treatment response. <i>Clinical Infectious Diseases</i> , 2013 , 56, 100-5	11.6	28
102	Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis. <i>Gut</i> , 2013 , 62, 760-5	19.2	132
101	Histological features in western patients with idiopathic non-cirrhotic portal hypertension. <i>Histopathology</i> , 2013 , 62, 1083-91	7.3	56
100	Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels. <i>Hepatology</i> , 2013 , 58, 872-80	11.2	163
99	Long-term effects of treatment and response in patients with chronic hepatitis C on quality of life. An international, multicenter, randomized, controlled study. <i>BMC Gastroenterology</i> , 2012 , 12, 11	3	26

98	Prevalence and risk factors of non-alcoholic fatty liver disease in the elderly: results from the Rotterdam study. <i>Journal of Hepatology</i> , 2012 , 57, 1305-11	13.4	144
97	Hepatitis B surface antigen declines and clearance during long-term tenofovir therapy in patients coinfecting with HBV and HIV. <i>Journal of Infectious Diseases</i> , 2012 , 206, 974-80	7	57
96	Evaluation of transient elastography for fibrosis assessment compared with large biopsies in chronic hepatitis B and C. <i>Liver International</i> , 2012 , 32, 622-8	7.9	58
95	Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a. <i>Journal of Hepatology</i> , 2012 , 56, 1006-1011	13.4	133
94	Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B. <i>Gastroenterology</i> , 2012 , 142, 513-520.e1	13.3	134
93	Histological differentiation grade and microvascular invasion of hepatocellular carcinoma predicted by dynamic contrast-enhanced MRI. <i>Journal of Magnetic Resonance Imaging</i> , 2012 , 36, 641-7	5.6	58
92	Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B. <i>Hepatology</i> , 2012 , 56, 67-75	11.2	64
91	Continuous interferon- α 2b infusion in combination with ribavirin for chronic hepatitis C in treatment-experienced patients. <i>Antiviral Therapy</i> , 2012 , 17, 509-17	1.6	3
90	Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon- α 2b: relation to response and HBV genotype. <i>Antiviral Therapy</i> , 2012 , 17, 9-17	1.6	54
89	Potent immune activation in chronic hepatitis C patients upon administration of an oral inducer of endogenous interferons that acts via Toll-like receptor 7. <i>Antiviral Therapy</i> , 2012 , 17, 657-67	1.6	24
88	NcoI TNF- α gene polymorphism and TNF expression are associated with an increased risk of developing Barrett's esophagus and esophageal adenocarcinoma. <i>Scandinavian Journal of Gastroenterology</i> , 2012 , 47, 378-86	2.4	16
87	Functional single-nucleotide polymorphism of epidermal growth factor is associated with the development of Barrett's esophagus and esophageal adenocarcinoma. <i>Journal of Human Genetics</i> , 2012 , 57, 26-32	4.3	23
86	Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. <i>JAMA - Journal of the American Medical Association</i> , 2012 , 308, 2584-93	27.4	1089
85	Long-term follow-up of hepatitis B e antigen-negative patients treated with peginterferon α 2a: progressive decrease in hepatitis B surface antigen in responders. <i>European Journal of Gastroenterology and Hepatology</i> , 2012 , 24, 1012-9	2.2	10
84	Pegylated interferon results in higher serological, but not virological, response rates when compared to continuous entecavir. <i>Antiviral Therapy</i> , 2012 , 17, 1605-8	1.6	13
83	Endoscopic visible light spectroscopy: a new, minimally invasive technique to diagnose chronic GI ischemia. <i>Gastrointestinal Endoscopy</i> , 2011 , 73, 291-8	5.2	47
82	A comparison of two assays for quantification of Hepatitis B surface Antigen in patients with chronic hepatitis B. <i>Journal of Clinical Virology</i> , 2011 , 51, 175-8	14.5	45
81	Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir. <i>Journal of Hepatology</i> , 2011 , 54, 449-54	13.4	117

80	Serum markers and intestinal mucosal injury in chronic gastrointestinal ischemia. <i>Digestive Diseases and Sciences</i> , 2011 , 56, 506-12	4	22
79	HBV DNA suppression in HBeAg-positive chronic hepatitis B patients treated with peginterferon or placebo. <i>Journal of Medical Virology</i> , 2011 , 83, 1917-23	19.7	2
78	Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naïve patients with a partial virological response. <i>Hepatology</i> , 2011 , 54, 443-51	11.2	132
77	Comparison of non-invasive assessment to diagnose liver fibrosis in chronic hepatitis B and C patients. <i>Scandinavian Journal of Gastroenterology</i> , 2011 , 46, 962-72	2.4	43
76	Serum HBsAg decline during long-term potent nucleos(t)ide analogue therapy for chronic hepatitis B and prediction of HBsAg loss. <i>Journal of Infectious Diseases</i> , 2011 , 204, 415-8	7	107
75	A randomized controlled study of accelerated versus standard hepatitis B vaccination in HIV-positive patients. <i>Journal of Infectious Diseases</i> , 2011 , 203, 984-91	7	30
74	A randomized trial of peginterferon alpha-2a with or without ribavirin for HBeAg-negative chronic hepatitis B. <i>American Journal of Gastroenterology</i> , 2010 , 105, 1762-9	0.7	71
73	Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B. <i>Gastroenterology</i> , 2010 , 139, 491-8	13.3	156
72	Long-term therapy with tenofovir is effective for patients co-infected with human immunodeficiency virus and hepatitis B virus. <i>Gastroenterology</i> , 2010 , 139, 1934-41	13.3	104
71	Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues. <i>Journal of Hepatology</i> , 2010 , 52, 493-500	13.4	96
70	Factors determining successful engraftment of hepatocytes and susceptibility to hepatitis B and C virus infection in uPA-SCID mice. <i>Journal of Hepatology</i> , 2010 , 53, 468-76	13.4	64
69	Thrombocytopenia and the risk of bleeding during treatment with peginterferon alfa and ribavirin for chronic hepatitis C. <i>Journal of Hepatology</i> , 2010 , 53, 455-9	13.4	36
68	Relatively high risk for hepatocellular carcinoma in patients with primary biliary cirrhosis not responding to ursodeoxycholic acid. <i>European Journal of Gastroenterology and Hepatology</i> , 2010 , 22, 1495-502	2.2	33
67	Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. <i>Hepatology</i> , 2010 , 52, 454-61	11.2	188
66	The potent bile acid sequestrant colesevelam is not effective in cholestatic pruritus: results of a double-blind, randomized, placebo-controlled trial. <i>Hepatology</i> , 2010 , 52, 1334-40	11.2	71
65	Risk factors for infection during treatment with peginterferon alfa and ribavirin for chronic hepatitis C. <i>Hepatology</i> , 2010 , 52, 1225-31	11.2	45
64	Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. <i>Hepatology</i> , 2010 , 52, 1251-7	11.2	225
63	Prediction of the response to peg-interferon-alfa in patients with HBeAg positive chronic hepatitis B using decline of HBV DNA during treatment. <i>Journal of Medical Virology</i> , 2010 , 82, 1135-42	19.7	37

62	Increased incidence of early de novo cancer in liver graft recipients treated with cyclosporine: an association with C2 monitoring and recipient age. <i>Liver Transplantation</i> , 2010 , 16, 837-46	4.5	55
61	Trends in liver transplantation for primary biliary cirrhosis in the Netherlands 1988-2008. <i>BMC Gastroenterology</i> , 2010 , 10, 144	3	27
60	Discriminant analysis using a multivariate linear mixed model with a normal mixture in the random effects distribution. <i>Statistics in Medicine</i> , 2010 , 29, 3267-83	2.3	15
59	Baseline anti-NS4a antibodies in combination with on-treatment quantitative HCV-RNA reliably identifies nonresponders to pegylated interferon-ribavirin combination therapy after 4 weeks of treatment. <i>European Journal of Gastroenterology and Hepatology</i> , 2010 , 22, 1443-8	2.2	1
58	Early HBeAg loss during peginterferon alpha-2b therapy predicts HBsAg loss: results of a long-term follow-up study in chronic hepatitis B patients. <i>American Journal of Gastroenterology</i> , 2009 , 104, 2449-57	0.7	21
57	A randomized comparison of electrocautery incision with Savary bougienage for relief of anastomotic gastroesophageal strictures. <i>Gastrointestinal Endoscopy</i> , 2009 , 70, 849-55	5.2	93
56	Update on PADI trial: percutaneous transluminal angioplasty and drug-eluting stents for infrapopliteal lesions in critical limb ischemia. <i>Journal of Vascular Surgery</i> , 2009 , 50, 687-9	3.5	27
55	Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. <i>Gastroenterology</i> , 2009 , 136, 1281-7	13.3	311
54	Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. <i>Gastroenterology</i> , 2009 , 137, 2002-9	13.3	300
53	Long-term outcome of a covered vs. uncovered transjugular intrahepatic portosystemic shunt in Budd-Chiari syndrome. <i>Liver International</i> , 2008 , 28, 249-56	7.9	38
52	Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. <i>Gastroenterology</i> , 2008 , 135, 459-67	13.3	301
51	Endoscopic treatment of esophagogastric variceal bleeding in patients with noncirrhotic extrahepatic portal vein thrombosis: a long-term follow-up study. <i>Gastrointestinal Endoscopy</i> , 2008 , 67, 821-7	5.2	41
50	A prospective open study of the efficacy of high-dose recombinant hepatitis B rechallenge vaccination in HIV-infected patients. <i>Journal of Infectious Diseases</i> , 2008 , 197, 292-4	7	54
49	Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. <i>Hepatology</i> , 2008 , 47, 1856-62	11.2	226
48	Predicting treatment outcome following 24 weeks peginterferon alpha-2a/ribavirin therapy in patients infected with HCV genotype 1: utility of HCV-RNA at day 0, day 22, day 29, and week 6. <i>Hepatology</i> , 2007 , 45, 258-9	11.2	6
47	Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis. <i>Hepatology</i> , 2007 , 46, 388-94	11.2	87
46	Genetic characteristics of hepatitis B virus genotypes as a factor for interferon-induced HBeAg clearance. <i>Journal of Medical Virology</i> , 2007 , 79, 1055-63	19.7	37
45	Gamma-glutamyltransferase and rapid virological response as predictors of successful treatment with experimental or standard peginterferon-alpha-2b in chronic hepatitis C non-responders. <i>Liver International</i> , 2007 , 27, 1217-25	7.9	28

44	Generic and disease-specific health related quality of life of liver patients with various aetiologies: a survey. <i>Quality of Life Research</i> , 2007 , 16, 375-88	3.7	32
43	Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. <i>Annals of Internal Medicine</i> , 2007 , 147, 677-84	8	459
42	Modelling of Early Viral Kinetics and Pegylated Interferon- α 2b Pharmacokinetics in Patients with HBeAg-Positive Chronic Hepatitis B. <i>Antiviral Therapy</i> , 2007 , 12, 1285-1294	1.6	8
41	Patterns of viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: relation to treatment response. <i>Hepatology</i> , 2006 , 44, 721-7	11.2	57
40	Prognosis of ursodeoxycholic Acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients. <i>American Journal of Gastroenterology</i> , 2006 , 101, 2044-50	0.7	128
39	Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. <i>American Journal of Gastroenterology</i> , 2006 , 101, 297-303	0.7	203
38	Successful treatment with peginterferon alfa-2b of HBeAg-positive HBV non-responders to standard interferon or lamivudine. <i>American Journal of Gastroenterology</i> , 2006 , 101, 2523-9	0.7	23
37	Long-term clinical outcome and effect of glycyrrhizin in 1093 chronic hepatitis C patients with non-response or relapse to interferon. <i>Scandinavian Journal of Gastroenterology</i> , 2006 , 41, 1087-94	2.4	30
36	Biochemical and histological effects of 26 weeks of glycyrrhizin treatment in chronic hepatitis C: a randomized phase II trial. <i>Journal of Hepatology</i> , 2006 , 45, 539-46	13.4	66
35	Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. <i>Lancet, The</i> , 2005 , 365, 123-9	40	948
34	International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C. <i>Journal of Hepatology</i> , 2005 , 43, 250-7	13.4	127
33	Paired, quantitative measurements of hepatitis B virus DNA in saliva, urine and serum of chronic hepatitis B patients. <i>European Journal of Gastroenterology and Hepatology</i> , 2005 , 17, 1173-9	2.2	26
32	Clinical outcome after cyclosporine dose reduction based on C2 levels in long-term liver transplant patients. <i>Clinical Transplantation</i> , 2005 , 19, 537-42	3.8	4
31	Integrity of the anal sphincters after pouch-anal anastomosis: evaluation with three-dimensional endoanal ultrasonography. <i>Diseases of the Colon and Rectum</i> , 2005 , 48, 1728-35	3.1	15
30	Volume measurements of the anal sphincter complex in healthy controls and fecal-incontinent patients with a three-dimensional reconstruction of endoanal ultrasonography images. <i>Diseases of the Colon and Rectum</i> , 2005 , 48, 540-8	3.1	49
29	The Liver Disease Symptom Index 2.0; validation of a disease-specific questionnaire. <i>Quality of Life Research</i> , 2004 , 13, 1469-81	3.7	39
28	Fluvoxamine for fatigue in primary biliary cirrhosis and primary sclerosing cholangitis: a randomised controlled trial [ISRCTN88246634]. <i>BMC Gastroenterology</i> , 2004 , 4, 13	3	42
27	Determinants of survival and the effect of portosystemic shunting in patients with Budd-Chiari syndrome. <i>Hepatology</i> , 2004 , 39, 500-8	11.2	267

26	Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. <i>Hepatology</i> , 2004 , 39, 804-10	11.2	287
25	Reduction of relapse rates by 18-month treatment in chronic hepatitis C. A Benelux randomized trial in 300 patients. <i>Journal of Hepatology</i> , 2004 , 40, 689-95	13.4	34
24	Prior radiation and/or chemotherapy has no effect on the outcome of metal stent placement for oesophagogastric carcinoma. <i>European Journal of Gastroenterology and Hepatology</i> , 2004 , 16, 163-70	2.2	85
23	Metastases in supraclavicular lymph nodes in lung cancer: assessment with palpation, US, and CT. <i>Radiology</i> , 2004 , 232, 75-80	20.5	70
22	A replicon-based bioassay for the measurement of interferons in patients with chronic hepatitis C. <i>Journal of Virological Methods</i> , 2003 , 110, 201-9	2.6	152
21	Retreatment of hepatitis C non-responsive to interferon. A placebo controlled randomized trial of ribavirin monotherapy versus combination therapy with Ribavirin and Interferon in 121 patients in the Benelux [ISRCTN53821378]. <i>BMC Gastroenterology</i> , 2003 , 3, 24	3	15
20	Pretreatment intrahepatic CD8+ cell count correlates with virological response to antiviral therapy in chronic hepatitis C virus infection. <i>Journal of Infectious Diseases</i> , 2003 , 188, 1528-32	7	15
19	Viral dynamics in chronic hepatitis B patients during lamivudine therapy. <i>Liver</i> , 2002 , 22, 121-6		31
18	Viral dynamics in chronic hepatitis B patients treated with lamivudine, lamivudine-famciclovir or lamivudine-ganciclovir. <i>European Journal of Gastroenterology and Hepatology</i> , 2002 , 14, 1007-11	2.2	23
17	The influence of baseline characteristics on viral dynamic parameters in chronic hepatitis B patients treated with lamivudine. <i>Journal of Hepatology</i> , 2002 , 37, 253-8	13.4	30
16	Viral dynamics during and after entecavir therapy in patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2002 , 37, 137-44	13.4	61
15	Hepatitis C viral kinetics in difficult to treat patients receiving high dose interferon and ribavirin. <i>Journal of Hepatology</i> , 2001 , 34, 435-40	13.4	31
14	US and fluoroscopic-guided percutaneous jejunostomy: experience in 49 patients. <i>Journal of Vascular and Interventional Radiology</i> , 2000 , 11, 101-6	2.4	44
13	Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: analysis of individual patient data of six controlled trials. Eurohep Study Group for Viral Hepatitis. <i>Gastroenterology</i> , 1999 , 117, 408-13	13.3	128
12	Early prediction of response in interferon monotherapy and in interferon-ribavirin combination therapy for chronic hepatitis C: HCV RNA at 4 weeks versus ALT. <i>Journal of Hepatology</i> , 1999 , 30, 192-8	13.4	75
11	Prognostic factors and long-term effects of ursodeoxycholic acid on liver biochemical parameters in patients with primary biliary cirrhosis. Dutch Multi-Centre PBC Study Group. <i>Journal of Hepatology</i> , 1999 , 31, 256-62	13.4	39
10	Efficacy of interferon dose and prediction of response in chronic hepatitis C: Benelux study in 336 patients. <i>Journal of Hepatology</i> , 1998 , 28, 951-9	13.4	38
9	Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers. <i>Journal of Hepatology</i> , 1997 , 26, 961-6	13.4	193

8	HLA expression and tumor-infiltrating immune cells in uveal melanoma. <i>Graefels Archive for Clinical and Experimental Ophthalmology</i> , 1996 , 234, 34-42	3.8	65
7	The cervical spine in rheumatoid arthritis: relationship between neurologic signs and morphology of MR imaging and radiographs. <i>Skeletal Radiology</i> , 1996 , 25, 113-8	2.7	35
6	Quantification of right ventricular function with magnetic resonance imaging in children with normal hearts and with congenital heart disease. <i>American Heart Journal</i> , 1995 , 130, 828-37	4.9	153
5	Effect of blood group and HLA matching on pancreas graft survival with the use of UW solution. <i>Transplant International</i> , 1995 , 8, 366-373	3	8
4	Effect of blood group and HLA matching on pancreas graft survival with the use of UW solution. <i>Transplant International</i> , 1995 , 8, 366-73	3	1
3	Long-term results of atrial correction for transposition of the great arteries: Comparison of Mustard and Senning operations. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 1994 , 108, 363-372	1.5	121
2	Reproducible radiographs of acetabular prostheses. A method assessed in 35 patients. <i>Acta Orthopaedica</i> , 1994 , 65, 258-62		5
1	Neuroenteric peptides affect natural killer activity by intestinal lamina propria mononuclear cells. <i>Journal of Neuroimmunology</i> , 1993 , 42, 139-45	3.5	18